<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599298</url>
  </required_header>
  <id_info>
    <org_study_id>NMRC CSA 2015</org_study_id>
    <nct_id>NCT02599298</nct_id>
  </id_info>
  <brief_title>Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome</brief_title>
  <acronym>SGMT</acronym>
  <official_title>Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized, open-label clinical trial is to determine the impact of Sleep
      Study-Guided Multidisciplinary Therapy (SGMT, i.e. continuous positive airway pressure and
      behavioral therapy) for obstructive sleep apnea (OSA) in the sub-acute phase of acute
      coronary syndrome on cardiovascular outcomes. We hypothesize that SGMT will result in a lower
      (1) plasma NT-pro BNP and ST2 levels, (2) 10-year risk of cardiovascular mortality based on
      the European SCORE algorithm, and (3) cardiovascular event rate, when compared with Standard
      Therapy.

      OSA is an emerging cardiac risk factor and prognostic marker. We have reported that OSA is a
      prevalent and independent predictor of adverse outcomes in patients with acute coronary
      syndrome. In this clinical trial, a continuation of my research and publication trajectory,
      180 patients presenting with acute coronary syndrome will be randomly assigned to SGMT (n=90)
      or Standard Therapy (n=90) groups. Both groups will receive guideline-mandated treatment for
      acute coronary syndrome. Those assigned to SGMT will undergo a sleep study. Those found to
      have OSA will attend the SGMT clinic run by a multidisciplinary team. Advice on continuous
      positive airway pressure and behavioral therapy (weight loss, exercise, positional therapy,
      abstinence of alcohol and sleeping pills) will be given. The primary endpoint is plasma
      NT-pro BNP concentration at 6-month follow-up. The secondary endpoint is 10-year risk of
      cardiovascular mortality based on the European SCORE algorithm which includes age, sex,
      smoking status, systolic blood pressure, and serum total cholesterol or total/HDL-cholesterol
      ratio. Adverse cardiovascular events at 3-year follow-up will be determined.

      In our aging population with an increasing prevalence of obesity, OSA will potentially become
      an increasingly important contributor to cardiovascular disease. Leveraging the collective
      expertise of a team of cardiologists and sleep physicians, our work will benefit society by
      advancing our understanding of the cardiovascular benefits of screening for and treating OSA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute coronary syndrome is a leading cause of mortality and morbidity globally. The Principal
      Investigator (PI) has been conducting research on sleep medicine and cardiovascular disease
      since 2007. Our early work has shown that obstructive sleep apnea (OSA) is prevalent in
      patients presenting with an acute coronary syndrome, and carries negative prognostic
      implications. This Clinician Scientist Award application is centered on the potential
      cardiovascular benefits of a Sleep Study-Guided Multidisciplinary Therapy (SGMT) that
      includes continuous positive airway pressure (CPAP) and behavioral therapy for patients
      presenting with an acute coronary syndrome, which could lead to a potential paradigm shift in
      patient management during the sub-acute phase of the syndrome. For this application, we have
      assembled a team of experts in cardiovascular medicine and sleep medicine. Using the leverage
      of the synergistic expertise of the assembled leaders and the knowledge generated in the
      early part of the program, we will embark on a therapeutic trial.

      In this randomized trial, 180 patients presenting with an acute coronary syndrome will be
      recruited and randomized into SGMT versus standard therapy (without sleep study) groups. Both
      groups will be treated with a guideline-mandated therapy for acute coronary syndrome
      (including regular cardiology outpatient clinic visits after discharge). In those allocated
      to SGMT, an overnight sleep study using a level 3 portable diagnostic device will be carried
      out. Those with OSA (an estimated 75% according to the pilot data) will be treated with CPAP
      and behavioral therapy. Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels
      will be measured before hospital discharge and at 6-month follow-up. The 10-year risk of
      cardiovascular mortality based on the European cardiovascular risk score (SCORE), which
      includes age, sex, smoking status, systolic blood pressure, and serum total cholesterol or
      total/high-density lipoprotein (HDL)-cholesterol ratio, will be determined at baseline and at
      6-month follow-up.

      Our specific aims are to compare the effects of SGMT and standard therapy on:

        -  Plasma levels of NT-proBNP (Primary endpoint) and ST2. We hypothesize that SGMT will be
           associated with a lower plasma NT-proBNP and ST2 levels than standard therapy at 6-month
           follow-up.

        -  Systematic COronary Risk Evaluation (SCORE). We hypothesize that SGMT will be associated
           with a lower SCORE than standard therapy at 6-month follow-up.

        -  Incidence of major adverse cardiac events (extended study). We hypothesize that SGMT
           will be associated with a lower incidence of major adverse cardiac events at 3-year
           follow-up (an application for additional funding will be made to accomplish this aim).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of NT-proBNP</measure>
    <time_frame>6-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>European cardiovascular risk SCORE</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite clinical endpoint of cardiovascular death, myocardial infarction (Q-wave and non-Q wave), stroke, unplanned revascularization, and hospitalization for heart failure</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of ST2</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of hs-CRP</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Compliance to CPAP</measure>
    <time_frame>6-month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>SGMT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Therapy</intervention_name>
    <arm_group_label>SGMT arm</arm_group_label>
    <other_name>CPAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep-Study Guided Multidisciplinary Therapy</intervention_name>
    <arm_group_label>SGMT arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 21 years, admission with an acute coronary syndrome, competent informed consent,
             and the ability to follow all protocol procedures.

        Exclusion Criteria:

          -  Known OSA being treated by CPAP, recommended coronary artery bypass surgery,
             concomitant moderate to severe structural valve disease, clinical instability
             (decompensated hypotension, heart failure, shock, refractory ventricular arrhythmias,
             acute conduction system disease, implanted defibrillator, or left ventricular ejection
             fraction â‰¤ 30%), limited life expectancy (&lt; 1 year) due to a concomitant illness,
             prior or planned heart transplant or any other organ transplant, pregnancy or current
             nursing activity, or inability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chi-Hang Lee</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>April 29, 2018</last_update_submitted>
  <last_update_submitted_qc>April 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University, Singapore</investigator_affiliation>
    <investigator_full_name>Chi-Hang Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

